Impact of Pulmonary Follow-up After Stem Cell Graft

Allogeneic hematopoietic stem cell transplantation is the only possible treatment for many malignant and non-malignant hemopathies. The graft-versus-host immunological reaction (GvH) is a frequent and sometimes serious complication. The objective is to study whether a systematic and early follow-up by a lung specialist of allografted patients would allow an earlier diagnosis of GvH with pulmonary complications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematologic Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Croix-Rousse Hospital, Hospices Civils de Lyon

Lyon, 69004, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 years of age or older
patients with a hematopoietic stem cell transplantation

Exclusion criteria

Death within 100 days post-surgery

Treatment and study plan

Hematopoietic Stem Cell Transplantation

Procedure

Hematopoietic stem cell transplantation

Primary outcomes

Medical complications

Time frame: Medical complications, especially Graft-versus-Host reaction with pulmonary complications occurring within 100 days post-surgery are studied

100 days after allograft

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Impact of Systematic Pulmonary Follow-up After Hematopoietic Stem Cell Transplantation

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Nov 21, 2017
Registry last updated: Nov 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed